Anker SD, Butler J, Filippatos G, et al. - This study was sought to present the baseline characteristics of the EMPEROR‐Preserved cohort and correlates it with patients enrolled in prior heart failure with preserved ejection fraction (HFpEF) trials. Researchers designed an EMPEROR‐Preserved that is a phase III randomized, international, double‐blind, parallel‐group, placebo‐controlled trial including a total of 5,988 symptomatic HFpEF patients (left ventricular ejection fraction [LVEF] >40%) with and without type 2 diabetes mellitus. The outcomes exhibited that the EMPEROR‐Preserved cohort has a somewhat higher burden of co‐morbidities, lower LVEF, higher median NT‐proBNP, and greater use of mineralocorticoid receptor antagonists at baseline when compared with prior trials in HFpEF. In 2021, outcomes of the EMPEROR‐Preserved trial will be available.